On The Fly
|
The most talked about and… ShowHide Related Items >><< - 03/15/23
- Tyler Technologies chairman sells $2.44M in common stock
- 03/13/23
- Tyler Technologies CFO Miller sells 3,639 common shares
- 03/07/23
- Tyler Technologies renews digital government, payment solutions in Colorado
- 03/01/23
- Tyler Technologies acquires Safeground Analytics, terms undisclosed
- 03/17/23
- Novartis terminates collaboration and license pact with Sangamo
- 03/14/23
- Sangamo says substantially all SVB deposits transferred to other banks
- 02/22/23
- Sangamo sees FY23 operating expenses of $275M-$295M
- 02/22/23
- Sangamo provides evidence of clinical benefit in Phase 1/2 STAAR study
- 03/22/23
- Santander Bank raises prime rate to 8% from 7.75%
- 02/02/23
- Santander Bank raises prime rate to 7.75% from 7.5%
- 12/14/22
- Santander Bank raises prime rate to 7.5% from 7%
- 12/09/22
- FCA fines Santander UK GBP 107.7M for repeated anti-money laundering failures
- 02/22/23
- Reliance Steel director sells $9.78M in common stock
- 03/21/23
- Ono Pharmaceutical's tirabrutinib granted FDA orphan designation
- 02/22/23
- Cue Biopharma enters collaboration, option agreement with Ono Pharmaceutical
- 01/19/23
- Repare Therapeutics receives $1.5M payment from Ono Pharmaceuticals
- 11/07/22
- Fate announces exercise by ONO of option to FT825/ONO-8250
- 04/26/23
- Oculis opens new office in Boston, appoints Fang Li as SVP, regulatory affairs
- 04/04/23
- Oculis to host call to discuss late-stage pipeline, near-term milestones
- 03/16/23
- Oculis completes enrollment in Phase 3 OCS-01 OPTIMIZE trial
- 03/06/23
- European Biotech Acquisition Corp trading resumes
- 04/26/23
- Coinbase, Talos partner on solutions for institutional digital asset demand
- 04/17/23
- Crypto names slide as bitcoin retreats below $29,500
- 03/14/23
- Crypto names extend gains as bitcoin soars to nine-month high above $26,000
- 03/13/23
- Crypto names jump as bitcoin rallies above $22,500
- 01/04/23
- Mobileye in pact with Wistron NeWeb for software-defined imaging radars
- 10/31/22
- Mobileye CEO buys $10M in common stock
- 03/07/23
- International Paper rebrands on 125th anniversary
- 01/24/23
- International Paper to sell ownership in Ilim joint venture for $484M
- 04/24/23
- Intel 'the main loser' of Sapphire Rapids' lower demand, says Ming-Chi Kuo
- 04/18/23
- EU takes on US and Asia with EUR 43B chip subsidy plan
- 04/10/23
- Global PC shipments fell 29% in first quarter of 2023, IDC reports
- 03/22/23
- Intel's Chief Architect Raja Koduri leaving after six years, says Gelsinger
- 02/14/23
- Greenlight buys Tenet, exits Intel in Q4
- 02/13/23
- Parthenon Capital to acquire Global Payments' gaming division
- 02/10/23
- Global Payments announces new partnerships with Atlanta Braves, Atlanta Hawk
- 02/10/23
- Global Payments reauthorizes up to $1.5B of share repurchase capacity
- 04/16/23
- Gilead announces results from several COVID-19 clinical, real-world studies
- 03/23/23
- Gilead, Pionyr Immunotherapeutics change 2020 exclusive option agreements
- 03/21/23
- Kite announces primary OS analysis results of Phase 3 ZUMA-7 study
- 03/20/23
- Gilead exercises option to license Nurix's NX-0479
- 04/27/23
- FIS rises 7.2%
- 03/01/23
- GoDaddy and Worldpay team to launch 'omnicommerce solution' Commerce 360
- 02/14/23
- Third Point buys AIG, exits T-Mobile in Q4
- 02/14/23
- JANA Partners takes stake in Fidelity National, exits stake in Momentive Global
FBIN Fortune Brands Innovations - 01/23/23
- Fortune Brands Innovations backs prior FY22 EPS view $6.20-$6.30
- 01/23/23
- Stanley Black & Decker names Patrick Hallinan CFO, succeeding Corbin Walburger
- 01/23/23
- Fortune Brands Innovations appoints David Barry CFO. succeeding Hallinan
- 12/19/22
- Fortune Brands Innovations to replace First Solar in S&P 400 at open on 12/19
- 04/17/23
- Cogent Biosciences presents nonclinical data at AACR
- 03/17/23
- Cogent Biosciences treatment of mastocytosis granted orphan status
- 01/09/23
- Cogent Biosciences announces planned milestones for 2023
- 12/11/22
- Cogent Biosciences announces updated data from ongoing Phase 2 APEX trial
- 04/28/23 RBC Capital
- RBC upgrades International Paper to Outperform on 'compelling' valuation
- 04/28/23 RBC Capital
- International Paper upgraded to Outperform from Sector Perform at RBC Capital
- 03/15/23 Deutsche Bank
- International Paper price target lowered to $31 from $33 at Deustche Bank
- 02/03/23 UBS
- International Paper upgraded to Neutral from Sell at UBS
- 04/28/23 Wedbush
- Oculis initiated with an Outperform at Wedbush
- 04/28/23 Truist
- Intel price target raised to $32 from $29 at Truist
- 04/28/23 BMO Capital
- Intel price target raised to $32 from $28 at BMO Capital
- 04/28/23 Wedbush
- Intel upgraded to Neutral from Underperform at Wedbush
- 04/28/23 TD Cowen
- Intel price target raised to $31 from $26 at TD Cowen
- 04/28/23 Credit Suisse
- FIS price target lowered to $70 from $75 at Credit Suisse
- 04/28/23 Stephens
- FIS upgraded to Overweight from at Stephens on clearer path to value
- 04/28/23 Stephens
- FIS upgraded to Overweight from Equal Weight at Stephens
- 03/26/23 Barclays
- FIS price target lowered to $58 from $68 at Barclays
- 04/28/23 Deutsche Bank
- Mobileye price target lowered to $44 from $48 at Deutsche Bank
- 04/28/23 Citi
- Mobileye price target lowered to $71 from $77 at Citi
- 04/28/23 Mizuho
- Mobileye price target lowered to $39 from $42 at Mizuho
- 04/28/23 Barclays
- Mobileye price target lowered to $50 from $60 at Barclays
FBIN Fortune Brands Innovations - 04/28/23 Deutsche Bank
- Fortune Brands Innovations price target raised to $72 from $67 at Deutsche Bank
- 04/28/23 Jefferies
- Fortune Brands upgraded to Buy at Jefferies ahead of 'catch up trade'
- 04/28/23 Jefferies
- Fortune Brands Innovations upgraded to Buy from Hold at Jefferies
- 03/09/23 Credit Suisse
- Fortune Brands downgraded to Underperform from Neutral at Credit Suisse
- 04/28/23 HSBC
- Santander downgraded to Hold on Brazil headwinds at HSBC
- 04/28/23 HSBC
- Banco Santander downgraded to Hold from Buy at HSBC
- 04/27/23 UBS
- Banco Santander price target raised to EUR 5 from EUR 4.95 at UBS
- 04/27/23 Berenberg
- Banco Santander price target lowered to EUR 4 from EUR 4.20 at Berenberg
- 04/28/23 Wolfe Research
- Reliance Steel downgraded to Peer Perform from Outperform at Wolfe Research
- 02/17/23 BMO Capital
- Reliance Steel price target raised to $265 from $235 at BMO Capital
- 01/25/23 KeyBanc
- Reliance Steel price target raised to $235 from $225 at KeyBanc
- 01/04/23 BofA
- Reliance Steel reinstated with a Neutral at BofA
- 04/28/23 DA Davidson
- Tyler Technologies downgraded to Neutral from Buy at DA Davidson
- 04/28/23 Piper Sandler
- Tyler Technologies price target raised to $465 from $450 at Piper Sandler
- 04/28/23 Baird
- Tyler Technologies price target raised to $470 from $440 at Baird
- 04/28/23 Barclays
- Tyler Technologies price target raised to $415 from $370 at Barclays
- 04/28/23 BofA
- Sangamo downgraded to Underperform from Neutral at BofA
- 03/03/23 H.C. Wainwright
- Sangamo price target lowered to $15 from $25 at H.C. Wainwright
- 02/27/23 Wedbush
- Wedbush upgrades Sangamo to Outperform, raises price target to $16
- 02/27/23 Wedbush
- Sangamo upgraded to Outperform from Neutral at Wedbush
- 04/27/23 Berenberg
- MicroStrategy initiated with a Buy at Berenberg
- 02/03/23 Canaccord
- MicroStrategy price target raised to $400 from $372 at Canaccord
- 12/29/22 Jefferies
- MicroStrategy price target lowered to $110 from $140 at Jefferies
- 11/09/22 Jefferies
- MicroStrategy price target lowered to $140 from $175 at Jefferies
- 04/27/23 Baird
- Cogent Biosciences initiated with Outperform, $20 target at Baird
- 04/27/23 Baird
- Cogent Biosciences initiated with an Outperform at Baird
- 04/17/23 Wedbush
- Wedbush remains bullish on Cogent, says APEX Part 2 likely to succeed
- 03/27/23 H.C. Wainwright
- Cogent Biosciences assumed with a Buy at H.C. Wainwright
- 04/28/23 Piper Sandler
- Gilead assumed with an Overweight at Piper Sandler
- 04/12/23 Morgan Stanley
- Gilead price target raised to $85 from $81 at Morgan Stanley
- 04/05/23 Guggenheim
- InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA
- 03/30/23 SVB Securities
- Arcellx price target raised to $39 from $35 at SVB Securities
- 04/28/23 Citi
- Global Payments resumed with a Buy at Citi
- 04/24/23 KeyBanc
- Global Payments price target raised to $125 from $115 at KeyBanc
- 04/19/23 Baird
- Global Payments upgraded to Outperform from Neutral at Baird
- 04/18/23 JPMorgan
- Global Payments reinstated with Neutral from Overweight at JPMorgan
- 04/28/23 Goldman Sachs
- Ono Pharmaceutical downgraded to Sell from Neutral at Goldman Sachs
- 01/03/23 Jefferies
- Ono Pharmaceutical downgraded to Hold from Buy at Jefferies
- 08/12/22 Citi
- Ono Pharmaceutical downgraded to Neutral from Buy at Citi
- 04/26/23
- Tyler Technologies backs FY23 EPS view $7.50-$7.65, consensus $7.58
- 04/26/23
- Tyler Technologies reports Q1 adjusted EPS $1.76, consensus $1.69
- 02/15/23
- Tyler Technologies sees FY23 adjusted EPS $7.50-$7.65, consensus $7.75
- 02/15/23
- Tyler Technologies reports Q4 adjusted EPS $1.66, consensus $1.75
- 04/26/23
- Sangamo sees Q1 revenue $158M, consensus $24.06M
- 02/22/23
- Sangamo reports Q4 EPS (32c), consensus (36c)
- 11/03/22
- Sangamo reports Q3 EPS (34c), consensus (35c)
- 04/27/23
- Reliance Steel sees Q2 adjusted EPS $6.40-$6.60, consensus $6.72
- 04/27/23
- Reliance Steel reports Q1 adjusted EPS $6.37, consensus $5.76
- 02/16/23
- Reliance Steel sees Q1 adjusted EPS $5.40-$5.60, consensus $4.92
- 02/16/23
- Reliance Steel reports Q4 adjusted EPS $5.87, consensus $4.47
- 02/02/23
- MicroStrategy reports Q4 EPS ($21.93), consensus (13c)
- 11/01/22
- MicroStrategy reports Q3 EPS ($2.39), consensus 27c
- 04/27/23
- Mobileye lowers FY23 revenue view to $2.07B-$2.11B from $2.19B-$2.28B
- 04/27/23
- Mobileye reports Q1 adjusted EPS 14c, consensus 12c
- 01/26/23
- Mobileye sees FY23 revenue $2.19B-$2.28B, consensus $2.21B
- 01/26/23
- Mobileye reports Q4 adjusted EPS 27c, consensus 17c
- 04/27/23
- International Paper reports Q1 adjusted EPS 53c, consensus 45c
- 01/31/23
- International Paper reports Q4 adjusted EPS 87c, consensus 69c
- 04/27/23
- Intel sees Q2 EPS adjusted (4c), consensus 1c
- 04/27/23
- Intel reports Q1 adjusted EPS (4c), consensus (15c)
- 04/27/23
- Notable companies reporting after market close
- 02/22/23
- Intel backs Q1 EPS view (15c), consensus (15c)
- 02/10/23
- Global Payments sees FY23 adjusted EPS $10.25-$10.37, consensus $10.37
- 02/10/23
- Global Payments reports Q4 adjusted EPS $2.42, consensus $2.41
- 02/09/23
- Notable companies reporting before tomorrow's open
- 04/27/23
- Gilead backs FY23 adjusted EPS view $6.60-$7.00, consensus $6.84
- 04/27/23
- Gilead reports Q1 Biktarvy sales up 24% y/y
- 04/27/23
- Gilead Sciences reports Q1 adjusted EPS $1.37, consensus $1.54
- 04/27/23
- FIS sees FY23 EPS $5.76-$6.06 , consensus $5.85
- 04/27/23
- FIS sees Q2 EPS $1.45-$1.50 consensus $1.48
- 04/27/23
- FIS reports Q1 EPS $1.29, consensus $1.20
- 02/13/23
- FIS sees FY23 adjusted EPS $5.70-$6.00, consensus $6.57
FBIN Fortune Brands Innovations - 04/26/23
- Fortune Brands Innovations sees FY23 EPS $3.65-$3.85, consensus $3.67
- 04/26/23
- Fortune Brands Innovations reports Q1 EPS 66c, consensus 60c
- 02/16/23
- Fortune Brands Innovations sees FY23 EPS ex-items $3.60-$3.80, consensus $3.91
- 02/16/23
- Fortune Brands Innovations reports Q4 EPS ex-items $1.07, consensus $1.35
- 03/14/23
- Cogent Biosciences reports Q4 EPS (56c), consensus (52c)
- 11/14/22
- Cogent Biosciences reports Q3 EPS (50c), consensus (51c)
|